人表皮生长因子受体2表达和可切除胃癌患者预后关系的Meta分析  

Prognostic role of human epidermal growth factor receptor 2 in resectable gastric cancer：A Meta-analysis

作　　者：叶华[1] 陈平[1] 郑祺[1] 吴枫[1] 郑成[1] 

机构地区：[1]宁波市第二医院胃肠外科,315010

出　　处：《中华胃肠外科杂志》2015年第1期46-49,共4页Chinese Journal of Gastrointestinal Surgery

摘　　要：目的：探讨肿瘤组织中人表皮生长因子受体2（HER-2）表达与可切除胃癌预后的相关性。方法检索Pubmed、EMBASE、Cochrane Library、Web of Science、中国生物医学文献数据库、中国期刊全文数据库和万方数据库，在2013年7月前公开发表的HER-2表达和可切除胃癌预后关系的临床试验文献。应用State12.0软件进行Meta分析，采用Newcastle-Ottawa Scale量表对入选文献进行质量评价。结果9篇文献共4787例患者纳入研究，入选文献质量评分均6分以上。Meta分析结果显示，各研究间无明显异质性（P=0.347），HER-2表达不是影响可切除胃癌患者预后的独立危险因素（HR=1.16，95% CI：0.97~1.38，P=0.114）。结论 HER-2阳性表达可能不是影响可切除胃癌患者预后的独立危险因素。Objective To investigate the prognostic association of human epidermal growth factor receptor 2 （HER-2） with resectable gastric cancer. Methods The literature databases, such as PubMed, EMBASE, Cochrane Library, Web of Science, CBM,CNKI, and Wanfang database, were extensively searched to retrieve the clinical studies of HER-2 expression in resectable gastric cancer published before July, 2013. The association of HER-2 expression with overall survival （OS） was examined. The state 12.0 version software was used for meta-analysis. The quality of these studies were assessed using the Newcasthe-Ottawa scale. Results There were nine studies meeting the inclusion criteria for meta-analysis including 4787 cases and the scores of all studies are more than 6 points. Meta-analysis showed no significant heterogeneity （I2=10.6%, P=0.347） among these studies. There was no significant difference in overall survival between positive HER-2 and negative HER-2 patients （HR=1.16, 95%CI：0.97-1.38, P=0.114）. Conclusion HER-2 overexpression in the tumor is not identified as a significant prognostic factor in patients with resectable gastric cancer.

关 键 词：胃肿瘤 人表皮生长因子受体2 META分析 

分 类 号：R735.2[医药卫生—肿瘤]